{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:33:55Z","timestamp":1782124435097,"version":"3.54.5"},"reference-count":7,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pemphigus vulgaris (PV) is a severe autoimmune blistering disease involving the skin and mucous membranes. The response to therapy varies greatly amongst patients and treatment may be challenging. Rituximab is a chimeric monoclonal antibody that selectively targets cell surface antigen CD20, thus depleting mature B cells <jats:italic>in vivo<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We report the results of rituximab treatment in two patients with severe PV. In both patients, high\u2010dose oral prednisolone and adjuvant therapy with intravenous immunoglobulins and mycophenolate mofetil failed to control disease activity. Consequently, the patients were treated with two courses of four weekly intravenous infusions of rituximab (375\u00a0mg\/m<jats:sup>2<\/jats:sup>) with a 6\u2010month interval.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Clinical improvement was already noticeable 3\u20136\u00a0weeks after the first infusion. After the second course, complete remission was achieved. Oral prednisolone was reduced and treatment with mycophenolate mofetil was continued. The patients remained in full remission 6\u00a0months after the last rituximab infusion.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> These cases suggest that two courses rather than a single course of rituximab may be a preferable mode of treatment. Rituximab should be considered as a promising treatment option for recalcitrant PV.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2008.03423.x","type":"journal-article","created":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T10:41:47Z","timestamp":1202985707000},"page":"292-294","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Two courses of rituximab (anti\u2010CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris"],"prefix":"10.1111","volume":"47","author":[{"given":"Annesofie","family":"Faurschou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66829-8"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.08.006"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126273"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.009"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07646.x"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062930"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(06)80004-4"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2008.03423.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2008.03423.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:41:49Z","timestamp":1696884109000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2008.03423.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,14]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1365-4632.2008.03423.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03423.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,14]]},"assertion":[{"value":"2008-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}